Table 1 Baseline study group characteristics.

	Placebo^a N = 15	Azithromycin^a N = 15
Age, %
0 y	13	12
1 y	14	14
2 y	18	20
3 y	26	24
4 y	30	30
Female, %	45	48
Malaria seroprevalence, %^b
P. falciparum MSP-1₁₉	79	76
P. falciparum AMA1	67	61
P. falciparum GLURP-Ro	26	21
P. falciparum LSA1	11	8
P. falciparum CSP	5	4
P. falciparum HRP2	2	2
P. malariae MSP-1₁₉	13	12
P. ovale MSP-1₁₉	2	3
P. vivax MSP-1₁₉	1	2
Bacteria and protozoa seroprevalence, %^c
Campylobacter sp. p18 or p39	92	91
ETEC LTB	88	84
Salmonella sp. LPS serogroups B or D	48	45
Cryptosporidium sp. Cp17 or Cp23	85	83
Giardia sp. VSP-3 or VSP-5	77	76
Streptococcus sp. serogroup A SPEB	63	60

^aEstimates include 559 children in placebo communities and 555 children in azithromycin communities.
^bMalaria antibody seroprevalence was estimated among children ages 12–59 months (baseline Placebo N = 488, Azithromycin N = 486), per the age group used in the primary analysis.
^cBacteria and protozoan antibody seroprevalence estimated among children ages 6–24 months (ETEC LTB, baseline Placebo N = 201, Azithromycin N = 202) or among children ages 6–59 months (all others, baseline Placebo N = 532, Azithromycin N = 539), per the age groups used in the primary analysis.
^**Created with notebook https://osf.io/qeg4u.

Quick links

Search